Par Drugs and Chemicals Limited (PAR.NS)
INR 103.99
(4.61%)
INR 103.99
(4.61%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 228.17 Million INR | 25.73% |
| 2022 | 182.07 Million INR | 10.92% |
| 2021 | 162.54 Million INR | 1.28% |
| 2020 | 181.87 Million INR | 70.6% |
| 2019 | 94.48 Million INR | 16.45% |
| 2018 | 82.14 Million INR | 5.89% |
| 2017 | 80.21 Million INR | -8.97% |
| 2016 | 84.61 Million INR | 17.38% |
| 2015 | 71.87 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 43.08 Million INR | -28.2% |
| 2024 Q2 | 123.94 Million INR | 188.38% |
| 2023 Q2 | 73.62 Million INR | 78.18% |
| 2023 Q1 | 41.32 Million INR | -19.25% |
| 2023 Q3 | 52.29 Million INR | -28.98% |
| 2023 Q4 | 60.93 Million INR | 16.54% |
| 2023 FY | - INR | 25.73% |
| 2022 Q2 | 59.2 Million INR | 54.09% |
| 2022 Q4 | 51.17 Million INR | 56.56% |
| 2022 FY | - INR | 10.92% |
| 2022 Q1 | 38.42 Million INR | -14.85% |
| 2022 Q3 | 32.68 Million INR | -44.79% |
| 2021 Q1 | 41.65 Million INR | -4.46% |
| 2021 FY | - INR | 1.28% |
| 2021 Q4 | 45.12 Million INR | 24.93% |
| 2021 Q3 | 36.12 Million INR | -11.31% |
| 2021 Q2 | 40.72 Million INR | -2.23% |
| 2020 Q4 | 43.59 Million INR | 10.86% |
| 2020 Q3 | 39.32 Million INR | 0.72% |
| 2020 FY | - INR | 70.6% |
| 2020 Q1 | 39.04 Million INR | 84.57% |
| 2020 Q2 | 39.04 Million INR | 0.0% |
| 2019 Q4 | 21.15 Million INR | 0.0% |
| 2019 FY | - INR | 16.45% |
| 2019 Q3 | 21.15 Million INR | -18.91% |
| 2019 Q2 | 26.08 Million INR | 0.0% |
| 2019 Q1 | 26.08 Million INR | 42.76% |
| 2018 Q4 | 18.27 Million INR | 0.0% |
| 2018 FY | - INR | 5.89% |
| 2018 Q1 | 22.54 Million INR | 0.0% |
| 2018 Q2 | 22.54 Million INR | 0.0% |
| 2018 Q3 | 18.27 Million INR | -18.93% |
| 2017 FY | - INR | -8.97% |
| 2016 FY | - INR | 17.38% |
| 2015 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 681.59 Million INR | 66.524% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -1655.725% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 96.31% |
| FDC Limited | 3.38 Billion INR | 93.26% |
| Gufic Biosciences Limited | 1.48 Billion INR | 84.588% |
| Hikal Limited | 2.69 Billion INR | 91.525% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 96.675% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 91.246% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | 20.614% |
| Medico Remedies Limited | 129.09 Million INR | -76.75% |
| Nectar Lifesciences Limited | 1.53 Billion INR | 85.141% |
| RPG Life Sciences Limited | 1.28 Billion INR | 82.195% |
| Sequent Scientific Limited | 549.8 Million INR | 58.499% |
| Shilpa Medicare Limited | 2.58 Billion INR | 91.183% |
| Sigachi Industries Limited | 883.39 Million INR | 74.171% |
| Themis Medicare Limited | 562.6 Million INR | 59.443% |
| Unichem Laboratories Limited | 742.35 Million INR | 69.264% |
| Venus Remedies Limited | 711.8 Million INR | 67.944% |
| Wanbury Limited | 985.49 Million INR | 76.847% |
| ZIM Laboratories Limited | 462.09 Million INR | 50.622% |
| Lupin Limited | 36.96 Billion INR | 99.383% |
| Innova Captab Limited | 1.66 Billion INR | 86.323% |
| Ind-Swift Limited | 1.06 Billion INR | 78.577% |
| Bajaj HealthCare Limited | 406.23 Million INR | 43.832% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.631% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 108.086% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 90.318% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -30.425% |
| Morepen Laboratories Limited | 1.72 Billion INR | 86.78% |
| Laurus Labs Limited | 8 Billion INR | 97.15% |
| Aarti Drugs Limited | 3.24 Billion INR | 92.976% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 96.675% |
| Alembic Limited | 1.11 Billion INR | 79.561% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 97.627% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 97.989% |
| Vaishali Pharma Limited | 31.71 Million INR | -619.542% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 94.163% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 29.458% |
| Jubilant Pharmova Limited | 8 Billion INR | 97.15% |
| Eris Lifesciences Limited | 6.98 Billion INR | 96.734% |
| Windlas Biotech Limited | 781.72 Million INR | 70.811% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.835% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | 83.014% |
| Orchid Pharma Limited | 1.41 Billion INR | 83.922% |
| Albert David Limited | 1.04 Billion INR | 78.174% |
| Hester Biosciences Limited | 539.47 Million INR | 57.704% |
| Sakar Healthcare Limited | 393.26 Million INR | 41.98% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 95.122% |
| Procter & Gamble Health Limited | 3.07 Billion INR | 92.578% |
| Divi's Laboratories Limited | 25.43 Billion INR | 99.103% |
| Mankind Pharma Limited | 28.09 Billion INR | 99.188% |
| Neuland Laboratories Limited | 4.74 Billion INR | 95.194% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 97.556% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.594% |
| Wockhardt Limited | 1.08 Billion INR | 78.873% |
| Bal Pharma Limited | 345.59 Million INR | 33.976% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.742% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 84.573% |
| Alkem Laboratories Limited | 24.19 Billion INR | 99.057% |
| Valiant Laboratories Limited | 12.73 Million INR | -1691.145% |
| Ajanta Pharma Limited | 12.56 Billion INR | 98.184% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -99.134% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -405.201% |
| Granules India Limited | 8.6 Billion INR | 97.348% |
| Medicamen Biotech Limited | 245.66 Million INR | 7.118% |
| Ipca Laboratories Limited | 13.29 Billion INR | 98.284% |
| Brooks Laboratories Limited | 41.72 Million INR | -446.813% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 46.97% |
| Piramal Enterprises Limited | -3.86 Billion INR | 105.91% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 99.348% |
| NATCO Pharma Limited | 18.79 Billion INR | 98.786% |
| Suven Life Sciences Limited | -992.78 Million INR | 122.983% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 375.816% |
| Strides Pharma Science Limited | 3.76 Billion INR | 93.939% |
| Indoco Remedies Limited | 2.64 Billion INR | 91.38% |
| Alpa Laboratories Limited | 229.96 Million INR | 0.777% |
| Lasa Supergenerics Limited | -65.08 Million INR | 450.605% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 106.115% |